Hackensack Meridian Health
Quick facts
| Founded | 2016 |
|---|
Marketed products
- 18F-rhPSMA-7.3 · Oncology
18F-rhPSMA-7.3 is a fluorine-18 labeled imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable PET imaging detection. - Ceftriaxone treatment
- Ketamine Injectable Product · Anesthesia, Pain Management, Psychiatry
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the central nervous system.
Phase 3 pipeline
- Convalescent Plasma · Immunology/Infectious Disease
Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease.
Phase 2 pipeline
- Cryopreserved Umbilical Cord Allograft
- Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
- Fludarabine monophosphate, melphalan, Bortezomib · Oncology
Fludarabine monophosphate is a purine analog that interferes with DNA synthesis, melphalan is an alkylating agent that cross-links DNA, and Bortezomib is a proteasome inhibitor that blocks protein degradation. - Iscador*P
- LICEMD
- Lu-17-PSMA-617
Phase 1 pipeline
- Decitabine plus Fludarabine and Busulfan
- Stem Cell Educator Therapy
- Tamsulosin - 1 week
- Tamsulosin - 3 days
- Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
- Vorinostat, Lenalinomide and Dexamethasone
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: